CYDY News and Press, CytoDyn Inc From 09/20/21

Activist Group Made Numerous Concessions, Including Dissolving Schedule 13D Group and Making Corrective and New Disclosures New Disclosures Clearly Show Activist Group Has Been Misleading Shareholders Around Group’s Conflicts of Interest, Sources of Funding and Agenda ...

A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today announced th...

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of CytoDyn Inc. (OTCQB:CYDY) concerning the Company and its directors’ and officers’ possible violations of state laws. If you purchased CytoDyn Inc. stock, would like to learn more about...

Palm Beach, FL – September 14, 2021 – FinancialNewsMedia.com News Commentary – All across the globe, innumerable scientists are looking to beat COVID-19… the two main paths are to find better vaccines and to utilize better treatments. As with most vir...

An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients) VANCOUVER, Washington, Sept. 09, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing le...

A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY” or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today resp...

VANCOUVER, Washington, Sept. 02, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today ...

Activist Group Illegally Solicited Shareholders Continues Pattern by Rosenbaum/Patterson Group of Eschewing Transparency, Misleading Shareholders and Ignoring Proxy Rules The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDy...

Board and Management Team Have Initiated a Misguided, Deceptive Public Relations Campaign That Has Further Damaged Company’s Value and Credibility Urges Stockholders to Vote on the WHITE Proxy Card Today to Elect Group’s Five Highly Experienced Director Nominees ...

Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led the CMC strategy and successfully submitted a monoclonal antibody based BLA (Dupixent ...